2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：2227102-46-5 Product Name： Synonyms： EINECS: Molecular Formula： Molecular Weight：
Target:
In Vivo
In Vitro
Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations, regardless of HER2 overexpression [1]. Patritumab deruxtecan (0-100 nM) binds to the surface of all HER3 mutant variants and HER3WT MDA-MB-231 cells in a concentration-dependent manner but does not bind to HER3EV cells [1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
